卵巢癌生化复发验案1例

陈绅铭; 陈小凤; 肖静

意见反馈

您当前的位置：

首页 >

文章列表页 >

卵巢癌生化复发验案1例

中国中医药临床案例成果库 | 病例报告

上一篇: 王丽华治疗隐源性机化性肺炎1例

下一篇: 夏玉清教授运用益气养阴法治疗肺癌案例一则

卵巢癌生化复发验案1例
A Case Report of Biochemical Recurrent Ovarian Cancer
1.广州中医药大学第二临床医学院，广州 510006
2.广州中医药大学第二附属医院妇科，广州 510006
DOI：

扫描看全文

陈绅铭, 陈小凤, 肖静. 卵巢癌生化复发验案1例[DB/OL].（2023-10-26）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43053465&Fpath=home&index=0

CHEN Shenming, CHEN Xiaofeng, XIAO Jing. A Case Report of Biochemical Recurrent Ovarian Cancer[DB/OL].（2023-10-26）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43053465&Fpath=home&index=0
陈绅铭, 陈小凤, 肖静. 卵巢癌生化复发验案1例[DB/OL].（2023-10-26）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43053465&Fpath=home&index=0 DOI：

CHEN Shenming, CHEN Xiaofeng, XIAO Jing. A Case Report of Biochemical Recurrent Ovarian Cancer[DB/OL].（2023-10-26）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43053465&Fpath=home&index=0 DOI：

摘要

病史摘要,2,女性患者，28岁，诊断为左侧卵巢中分化粘液性囊腺癌，FIGO IA期。肿瘤标志物CA 72-4在第2个化疗周期后降到正常范围，但第4个化疗周期后上升到几乎是正常上限的2倍，之后的随访期间上升到基线的7倍。CA72-4在每次升高后使用切脉针灸+中药疗法约6周后，都能恢复到基线水平。至今患者结束化疗6年，结束中药针灸治疗4年，仍在无疾病状态。这个案例强调了切脉针灸+中药治疗作为卵巢癌生化复发治疗方案的潜在效用，值得进一步研究。中医诊断　卵巢癌（脾肾阳虚，瘀热互结）西医诊断　卵巢中分化粘液性囊腺癌 IA 期干预措施　切脉针灸+中药综合治疗。疗效转归　无病生存期大于6年。

Abstract

Summary of case history,　A 28-year-old woman was diagnosed with a moderately differentiated mucinous cystadenocarcinoma of the left ovary (FIGO stage IA). The tumor marker CA 72-4 decreased to the normal range after the second cycle, but increased to almost 2 times the upper limit of normal after the fourth chemotherapy cycle, and increased to 7 times the baseline during the subsequent follow-up period. CA72-4 could return to the baseline level after about 6 weeks of acupuncture combined with Chinese medicine therapy after each rise. So far, the patient has finished chemotherapy for 6 years and completed acupuncture combine with Chinese medicine treatments for 4 years, and is still in a disease-free state. This case emphasizes the potential utility of acupuncture combine with traditional Chinese medicine as a treatment scheme for biochemical recurrence of ovarian cancer and deserves further study.,TCM diagnosis,　ovarian cancer; spleen and kidney yang deficiency, blood stasis and heat accumulation,Western medicine diagnosis,　moderately differentiated mucinous cystadenocarcinoma of ovary(FIGO stage IA),Therapeutic methods,　pulse acupuncture and traditional Chinese herbal medicine,Clinical outcomes,　disease-free survival,>,6 y,.

关键词

卵巢癌生化复发中药病例报告切脉针灸

Keywords

ovarian cancerbiochemical recurrencetraditional Chinese medicinecase reportpuls acupunctureChinese medicine

references

Hising C, Anjegard IM, Einhorn N. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients[J]. Am J Clin Oncol. 1991;14:111–4.

Tuxen MK, Soletormos G, Dombernowsky P. Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up[J]. Scand J Clin Lab Invest. 2002;62:177–88.

Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer: a randomised trial[J].Lancet 2010,376:1155-1163.

Kristeleit R, Davidenko I, Shirinkin V, et al. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer[J]. Gynecol Oncol. 2017;146(3):484-490.

Wang Z, Huang Y, Long L, et al. Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression[J]. J Ovarian Res. 2021;14(1):91.

陈小凤,肖静,俞云.俞云切脉针灸对生化复发型卵巢癌的针药结合治疗心得[J].时珍国医国药,2019,30(2):474-476.

Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer[J]. N Engl J Med, 2019, 381(25): 2416-2428.

Penson R T, Valencia R V, Cibula D, et al. Olaparib Versus Nonplatinum Chemotherapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial[J]. J Clin Oncol, 2020, 38(11): 1164-1174.

Vetter M HHays J L. Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions[J]. Clin Ther, 2018, 40(3): 361-371.

俞云.切脉针灸治癌[M].合肥: 安徽科学技术出版社,1994.

俞云.切脉针灸－黄帝内经针法[M].北京: 人民卫生出版社,2013.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中医药治疗宫颈鳞癌术后及放化疗后SCC升高1例

温阳化积法治疗卵巢癌生化复发患者1例

阮诗玮“角药”在肾系疾病中的运用

中医药调理宫腔粘连术后自然怀孕病例报告

从“斑出阳明”辨治儿童红皮病1例报告